Cell BioEngines, Inc
Monday, February 26, 2024
A Clinical-stage Biotech Company Developing ‘Off-the-shelf’ Non-gene Modified Hematopoietic Stem Cells & Its Derived Immune Cell Therapies For Cancer Patients.
CEO/Top Company Official
Dr. Ajay Vishwakarma
Lead Product in Development
Hematopoietic Cell Transplantation (HCT) for AML and MDS patients.
Development Phase of Primary Product
Number Of Unlicensed Products